US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results

Sanara MedTech Inc. (NASDAQ:SMTI) defied analyst predictions to release its quarterly results, which were ahead of market expectations. Revenues and losses per share were both better than expected, with revenues of US$22m leading estimates by 4.7%. Statutory losses were smaller than the analystexpected, coming in at US$0.34 per share. This is an important time for investors, as they can track a company's performance in its report, look at what expert is forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analyst is expecting for next year.

Check out our latest analysis for Sanara MedTech

Taking into account the latest results, the consensus forecast from Sanara MedTech's lone analyst is for revenues of US$99.1m in 2025. This reflects a substantial 27% improvement in revenue compared to the last 12 months. Per-share losses are expected to explode, reaching US$1.18 per share. Yet prior to the latest earnings, the analyst had been forecasting revenues of US$96.2m and losses of US$1.17 per share in 2025.

The consensus price target fell 10% to US$44.00as the analyst signal that ongoing losses are likely to weigh on the stock price.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Sanara MedTech's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Sanara MedTech's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 21% growth on an annualised basis. This is compared to a historical growth rate of 40% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 8.2% annually. Even after the forecast slowdown in growth, it seems obvious that Sanara MedTech is also expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analyst reconfirmed their loss per share estimates for next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. Furthermore, the analyst also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At least one analyst has provided forecasts out to 2026, which can be seen for free on our platform here.

You still need to take note of risks, for example - Sanara MedTech has 2 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.